BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 03:02:26 2024-06-14 am EDT | ||
| 736.8 EUR | -0.01% |
|
| Current month | +0.15% | ||
| 1 month | +0.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 736.8 | -0.01% |
| 24-06-13 | 737 | +0.01% |
| 24-06-12 | 736.8 | 0.00% |
| 24-06-11 | 736.8 | +0.06% |
| 24-06-10 | 736.4 | -0.07% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 03:02 am EDT
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CH8 |
| ISIN | DE000HD0CH86 |
| Date issued | 2023-11-01 |
| Strike | 750 kr |
| Maturity | 2024-12-20 (190 Days) |
| Parity | 1 : 1 |
| Emission price | 651.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 737.3 € |
|---|---|
| Lowest since issue | 639.3 € |
| Spread | 1.7 € |
| Spread % | 0.23% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
979.7
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.13%
- Stock Market
- Certificates
- Certificat
